McKesson Stock Shoots To Record High. Health Products Giant Shows Improved Price Strength

Company Performance - McKesson's stock reached a record high of $748.75 after breaking out of a flat base, continuing to rise to approximately $761 [1][3] - The company reported a 5% earnings gain to $8.26 per share and a 23% increase in revenue to $97.8 billion last quarter [1] - Analyst consensus predicts continued double-digit revenue growth for the remainder of the year [1] Relative Strength Ratings - McKesson's Relative Strength (RS) Rating improved from 66 to 79, nearing the 80 RS Rating threshold that indicates strong market performance [2] - The company holds a B+ Accumulation/Distribution Rating and a 91 EPS Rating out of 99, with a Composite Rating of 78 [2] Industry Position - McKesson ranks No. 2 in the Medical-Wholesale Drugs industry group, with Cencora as the top-ranked stock [4] - The medical wholesale drugs group ranks 166 out of 197 industry groups according to IBD [4]